We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark
Read MoreHide Full Article
Hologic, Inc. (HOLX - Free Report) announced an extension of its LOCalizer radiofrequency identification (“RFID”) tag’s CE Mark. Under the extended approval, the tag can now be implanted more than 30 days prior to breast-conserving surgery. The CE Mark was first received in February 2019 to be implanted within 30 days prior to the surgery.
The company believes that the new tag for long-term placement will provide more flexibility and convenience to patients as well as care providers, thus resulting in a favorable outcome. Notably, breast lesion localization methods are a component of Hologic’s breast health business.
The latest approval is expected to act as an impetus for the company to strengthen the position in the global breast lesion localization methods market.
Why is the Extension Significant?
The LOCalizer, which is a wire-free guidance system, is a non-radioactive, radiofrequency localization system, intended for precise marking and targeting of lesions in breast-conserving surgery. It is an upgradation from the traditional wire-guided localization method (which required placing the wire on the day of the surgery), thus making it possible for patients to undergo fewer interventional surgeries.
Other Developments in Breast Health Portfolio
Hologic has been focusing on its aforementioned business for quite some time now. The company acquired Faxitron Bioptics (a digital specimen radiography major) in July 2018. The LOCalizer system has become part of Hologic’s expanding breast health segment since acquired. Notably, the system is manufactured by Health Beacons and is distributed exclusively by Hologic. In January 2019, Hologic received the FDA approval for its LOCalizer.
Hologic partnered with MagView (a key mammography information solutions provider) in July to develop Unifi EQUIP. It is an automated solution facilitating compliance with the FDA’s Enhancing Quality Using the Inspection Program (EQUIP) guidance. It will be available to customers as part of the integrated Unifi product portfolio of Hologic.
In November, Hologic announced plans to launch Unifi Workspace — a comprehensive breast diagnostic reading solution. Further, the company received the FDA clearance for 3DQuorum Imaging Technology, which is powered by Genius AI, in the same month.
Apart from these, Hologic launched products like the Trident HD specimen radiography system on a global scale and the Unifi Analytics in the United States.
Industry Prospects
Per a report by ResearchAndMarkets, the global breast lesion localization methods market size is anticipated to reach $1.58 billion by 2025, witnessing a CAGR of 13.3%. The key factors driving the market are the rising incidents of breast cancer and the subsequent reimbursement policies (both government and non-government) for breast cancer diagnostics, biopsy, examination and other medical procedures.
Given the current market potential for the breast health business, the latest European approval for long-term placement in breast lesions has come at the right time.
Price Performance
The company’s shares have gained 15.7% in the past year compared with the industry’s growth of 8.1%.
Zacks Rank & Key Picks
Currently, Hologic carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , National Vision Holdings, Inc (EYE - Free Report) and ResMed Inc (RMD - Free Report) .
Haemonetics currently has a Zacks Rank #2 (Buy) and a projected long-term earnings growth rate of 13.5%.
ResMed’s long-term earnings growth rate is estimated at 12.9%. It currently flaunts a Zacks Rank #1.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.
This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.
Image: Bigstock
Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark
Hologic, Inc. (HOLX - Free Report) announced an extension of its LOCalizer radiofrequency identification (“RFID”) tag’s CE Mark. Under the extended approval, the tag can now be implanted more than 30 days prior to breast-conserving surgery. The CE Mark was first received in February 2019 to be implanted within 30 days prior to the surgery.
The company believes that the new tag for long-term placement will provide more flexibility and convenience to patients as well as care providers, thus resulting in a favorable outcome. Notably, breast lesion localization methods are a component of Hologic’s breast health business.
The latest approval is expected to act as an impetus for the company to strengthen the position in the global breast lesion localization methods market.
Why is the Extension Significant?
The LOCalizer, which is a wire-free guidance system, is a non-radioactive, radiofrequency localization system, intended for precise marking and targeting of lesions in breast-conserving surgery. It is an upgradation from the traditional wire-guided localization method (which required placing the wire on the day of the surgery), thus making it possible for patients to undergo fewer interventional surgeries.
Other Developments in Breast Health Portfolio
Hologic has been focusing on its aforementioned business for quite some time now. The company acquired Faxitron Bioptics (a digital specimen radiography major) in July 2018. The LOCalizer system has become part of Hologic’s expanding breast health segment since acquired. Notably, the system is manufactured by Health Beacons and is distributed exclusively by Hologic. In January 2019, Hologic received the FDA approval for its LOCalizer.
Hologic partnered with MagView (a key mammography information solutions provider) in July to develop Unifi EQUIP. It is an automated solution facilitating compliance with the FDA’s Enhancing Quality Using the Inspection Program (EQUIP) guidance. It will be available to customers as part of the integrated Unifi product portfolio of Hologic.
In November, Hologic announced plans to launch Unifi Workspace — a comprehensive breast diagnostic reading solution. Further, the company received the FDA clearance for 3DQuorum Imaging Technology, which is powered by Genius AI, in the same month.
Apart from these, Hologic launched products like the Trident HD specimen radiography system on a global scale and the Unifi Analytics in the United States.
Industry Prospects
Per a report by ResearchAndMarkets, the global breast lesion localization methods market size is anticipated to reach $1.58 billion by 2025, witnessing a CAGR of 13.3%. The key factors driving the market are the rising incidents of breast cancer and the subsequent reimbursement policies (both government and non-government) for breast cancer diagnostics, biopsy, examination and other medical procedures.
Given the current market potential for the breast health business, the latest European approval for long-term placement in breast lesions has come at the right time.
Price Performance
The company’s shares have gained 15.7% in the past year compared with the industry’s growth of 8.1%.
Zacks Rank & Key Picks
Currently, Hologic carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (HAE - Free Report) , National Vision Holdings, Inc (EYE - Free Report) and ResMed Inc (RMD - Free Report) .
Haemonetics currently has a Zacks Rank #2 (Buy) and a projected long-term earnings growth rate of 13.5%.
National Vision’s long-term earnings growth rate is estimated at 17.8%. The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ResMed’s long-term earnings growth rate is estimated at 12.9%. It currently flaunts a Zacks Rank #1.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.
This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.
See their latest picks free >>